Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities (2017 - 2026)

Crinetics Pharmaceuticals' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $389.9 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 8686.91% year-over-year to $389.9 million in Q1 2026; TTM through Mar 2026 was $426.0 million, a 31.89% decrease from a year earlier, with the FY2025 full-year figure at $40.6 million, down 96.0% from the prior year.
• Cash from Financing Activities improved to $389.9 million in Q1 2026 per CRNX's latest filing, from $26.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $556.2 million in Q4 2024 and bottomed at $115000.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $12.7 million (2023), against an average of $115.2 million.
• Across the five-year window, Cash from Financing Activities sank 99.93% in 2022 and jumped 81216.94% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $115000.0 in 2022, then surged by 34870.43% to $40.2 million in 2023, then soared by 1283.12% to $556.2 million in 2024, then plunged by 95.32% to $26.0 million in 2025, then soared by 1397.5% to $389.9 million in 2026.
• Per Business Quant, the three latest CRNX Cash from Financing Activities figures stand at $389.9 million (Q1 2026), $26.0 million (Q4 2025), and $3.1 million (Q3 2025).